Also known as: beta thalassemia, alpha thalassemia, thalassaemia, Cooley's anemia
Symptoms of beta-thalassemia major typically emerge after age 6 months. Inherited as autosomal recessive. Most common in people of Mediterranean, North African, Middle Eastern, and Asian descent.
Gene therapy for thalassemia has shown remarkable success in clinical trials, with many patients achieving complete hematologic correction and elimination of transfusion dependence. The FDA has approved CTX001, a lentiviral vector-based gene therapy for beta-thalassemia major. Luspatercept, an erythroid maturation agent, has also shown benefit in reducing transfusion dependence. The Thalassemia International Federation and patient organizations maintain comprehensive trial information. If you have thalassemia major, discuss with your hematologist about whether you are a candidate for gene therapy or other emerging therapies. Genetic counseling is recommended for affected individuals and families. Current standard care includes transfusion therapy, iron chelation, and monitoring for complications.
Sickle cell disease is an inherited blood disorder where hemoglobin polymerizes under low oxygen, causing red blood cell...
Severe combined immunodeficiency is a rare genetic disorder affecting both T cell and B cell immune function, resulting ...
Mastocytosis is a rare hematological disorder characterized by clonal expansion of mast cells in bone marrow, organs, an...